Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
10592studies shown
Showing 2,689-2,700 of 10,592
Drug study icon
CompletedNCT03866174

Psilocybin for Major Depressive Disorder (MDD)

This study is completed in the United States. It is testing psilocybin for depression.

In United States
DepressionDrugA study involving a medication or substance.From 21 Years to 65 Years
Countries
United States
Sponsor
Usona Institute
Condition
Depression
Drug study icon
Active Not RecruitingNCT06407635

Psilocybin for PTSD

This study is active but not recruiting in the United States. It is testing psilocybin for PTSD.

In United States
PTSDDrugFrom 21 Years to 75 Years
Countries
United States
Sponsor
Johns Hopkins University
Condition
PTSD
Drug study icon
TerminatedNCT03352453

Rapastinel for depression

This study was terminated in the United States. It is testing rapastinel for depression.

In United States
Depression, SuicidalityDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Naurex, Inc, an affiliate of Allergan plc
Condition
Depression, Suicidality
Drug study icon
CompletedNCT00167479

Risperidone Monotherapy in Bipolar Anxiety

This study is completed in the United States. It is testing risperidone Monotherapy for anxiety.

In United States
Bipolarity, AnxietyDrugOver 18 Years
Countries
United States
Sponsor
University of South Florida
Condition
Bipolarity, Anxiety
Drug study icon
CompletedNCT00616798

RO4917838 for schizophrenia

This study is completed in the United States, in France, in Austria, .... It is testing RO4917838 for schizophrenia.

In United States
SchizophreniaDrugFrom 18 Years to 60 Years
Countries
United States, France, Austria, ...
Sponsor
Hoffmann-La Roche
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.